Moderna, Inc. - Common Stock (NQ:MRNA)

190.01 +1.07 (+0.57%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

99 100 Next >

3 Reasons to Avoid MRNA and 1 Stock to Buy Instead

February 24, 2026

What a fantastic six months it’s been for Moderna. Shares of the company have skyrocketed 99.8%, hitting $50.65. This was partly due to its solid quarterly results, and the run-up might have investors...

Via StockStory

Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

February 23, 2026

From Tectonic Therapeutic

Via GlobeNewswire

Moderna Stock Is Trading Higher Today: What's Going On? ↗

February 23, 2026

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Monday. Piper Sandler boosted its price target on the stock to $69 from $63 while reiterating an Overweight rating.

Via Benzinga

Here's Why I Wouldn't Touch Moderna With a 10‑Foot Pole Until Its Next Growth Engine Is Clear ↗

February 23, 2026

Moderna made a fortune with COVID vaccines, but revenue has since declined.

Via The Motley Fool

Moderna Inc (NASDAQ:MRNA) Beats Q4 2025 Estimates Amid Post-Pandemic Transition ↗

February 13, 2026

Via Chartmill

Billionaire Philippe Laffont Just Dumped CoreWeave and Opened a Position in a Stock That Soared Nearly 50% in January. ↗

February 21, 2026

Laffont's new addition may represent an exciting recovery story.

Via The Motley Fool

Topics Artificial Intelligence

Friday's session: gap up and gap down stock in the S&P500 index ↗

February 20, 2026

Via Chartmill

Moderna’s Q4 Earnings Call: Our Top 5 Analyst Questions

February 20, 2026

Moderna’s fourth quarter results were received positively by the market, reflecting a combination of better-than-expected revenue and effective cost management. Management cited the successful U.S....

Via StockStory

Topics Earnings

Uncover the latest developments among S&P500 stocks in today's session. ↗

February 19, 2026

Via Chartmill

Moderna to Present at Upcoming Conferences in March 2026

February 19, 2026

Via ACCESS Newswire

3 Once-in-a-Decade Buying Opportunities ↗

February 18, 2026

Bargain-hunters should give these stocks a close look.

Via The Motley Fool

Topics Artificial Intelligence

Why Moderna (MRNA) Stock Is Trading Up Today

February 18, 2026

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 5.9% in the afternoon session after the U.S. Food and Drug Administration (FDA) reversed an earlier decision and agreed to review the...

Via StockStory

Topics Economy

These S&P500 stocks are moving in today's session ↗

February 18, 2026

Via Chartmill

Why Moderna Stock Just Popped ↗

February 18, 2026

So the FDA will consider Moderna's flu vaccine application after all. Does this make Moderna stock a buy?

Via The Motley Fool

Wednesday's session: gap up and gap down stock in the S&P500 index ↗

February 18, 2026

Via Chartmill

Moderna Stock Gains After FDA Accepts Company’s Revised Flu Vaccine Application For Review ↗

February 18, 2026

The FDA has now accepted the biologics license application for review, setting a Prescription Drug User Fee Act goal date of Aug. 5, 2026.

Via Stocktwits

What's going on in today's pre-market session: S&P500 movers ↗

February 18, 2026

Via Chartmill

Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission

February 18, 2026

Via ACCESS Newswire

3 Stocks Under $50 with Warning Signs

February 17, 2026

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some...

Via StockStory

The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot

February 17, 2026

As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a...

Via MarketMinute

Topics Artificial Intelligence Economy Initial Public Offering

Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline

February 17, 2026

As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based...

Via Finterra

Topics Economy Intellectual Property

Shopify's Whiplash Day ↗

February 17, 2026

It looked like Shopify's stock was headed for a great day when it reported earnings, only for the stock to give up all its gains and then some when management started talking on the conference call.

Via The Motley Fool

Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE

February 17, 2026

Via ACCESS Newswire

3 Cash-Burning Stocks That Fall Short

February 15, 2026

Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even...

Via StockStory

Topics Bankruptcy

MRNA Q4 Deep Dive: New Vaccines, Cost Controls, and Pipeline Milestones Shape Outlook

February 14, 2026

Biotechnology company Moderna (NASDAQ:MRNA) announced better-than-expected revenue in Q4 CY2025, but sales fell by 29.8% year on year to $678 million. Its non-GAAP loss of $2.11 per share was 20.2%...

Via StockStory

Moderna Shares Surge as Aggressive Cost-Cutting and Post-Pandemic Pivot Take Hold in Q4 Results

February 13, 2026

Moderna Inc. (NASDAQ: MRNA) shares jumped 8% in early trading on February 13, 2026, after the biotechnology pioneer reported fourth-quarter 2025 financial results that exceeded Wall Street’s...

Via MarketMinute

Topics Earnings

Moderna, Vertex Pharmaceuticals, Integra LifeSciences, Baxter, and Molina Healthcare Shares Are Soaring, What You Need To Know

February 13, 2026

A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a...

Via StockStory

Topics Economy

Top S&P500 movers in Friday's session ↗

February 13, 2026

Via Chartmill

Friday's session: top gainers and losers in the S&P500 index ↗

February 13, 2026

Via Chartmill

Moderna (MRNA) Q4 2025 Earnings Call Transcript ↗

February 13, 2026

Moderna (MRNA) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.